Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an announcement.
Dong-E-E-Jiao, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its unaudited financial results for the first quarter of 2025, showing a revenue increase to RMB 1.72 billion and a net profit of RMB 425 million. Despite a decrease in cash and cash equivalents, the company maintained strong total assets and owner’s equity, indicating stable financial health. Stakeholders are advised to exercise caution as these figures are unaudited and may be subject to adjustments.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products. The company holds significant equity interests in Dong-E-E-Jiao, a company listed on the Shenzhen Stock Exchange, known for its production of traditional Chinese medicine products.
YTD Price Performance: -19.26%
Average Trading Volume: 1,550
Technical Sentiment Signal: Buy
Current Market Cap: €3.5B
For detailed information about 3320 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test
- “Direct Result of Your Feedback….” Microsoft Stock (NASDAQ:MSFT) Slips as The Option to Skip Updates Emerges